Physician profile
Pardeep Masuta
NPI 1881077063
$8,092.74
in general payments reported to CMS, 2019-2025
32 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $437 · 2022: $1,764 · 2023: $2,223 · 2024: $2,447 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,364 · Travel and Lodging: $865 · Consulting Fee: $400 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,363.83 |
| Travel and Lodging | $864.59 |
| Consulting Fee | $400.00 |
| Education | $263.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $958.21 | 2023-2025 | Galaxy |
| Glaxosmithkline, LLC. | $884.63 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $845.37 | 2022-2025 | Opsumit, Uptravi, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $818.26 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Mallinckrodt Hospital Products INC. | $640.19 | 2022-2025 | Acthar, Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.59 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $531.81 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $361.88 | 2021-2025 | Dupixent |
| Genzyme Corporation | $337.53 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $232.80 | 2022-2023 | |
| Amgen INC. | $201.32 | 2022-2025 | Tezspire, Lumakras |
| Merck Sharp & Dohme LLC | $185.79 | 2024-2025 | Winrevair, Keytruda |
| Takeda Pharmaceuticals U.S.A., INC. | $185.18 | 2021-2025 | Glassia |
| Harmony Biosciences LLC | $154.51 | 2021-2025 | Wakix |
| United Therapeutics Corporation | $141.39 | 2021-2025 | Tyvaso, Tyvaso |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $131.91 | 2021-2025 | Vest Therapy Und |
| Electromed, INC. | $110.52 | 2022-2025 | Smartvest |
| Mylan Specialty L.P. | $107.81 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $94.95 | 2023 | |
| Verona Pharma, INC. | $80.03 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $66.52 | 2022-2024 | Purified Cortrophin Gel |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $58.99 | 2025 | |
| Grifols USA, LLC | $58.29 | 2024 | Prolastin-C Liquid |
| Baxter Healthcare | $53.55 | 2022 | |
| Pharming Healthcare, INC. | $48.20 | 2023 | Ruconest |
| Pfizer INC. | $46.88 | 2022-2024 | |
| Vifor Pharma, INC. | $44.56 | 2024-2025 | Zemaira |
| Tactile Systems Technology INC | $31.05 | 2025 | Nimbl, Flexitouch Plus |
| Insmed, INC. | $23.30 | 2024 | Arikayce |
| Boston Scientific Corporation | $21.90 | 2023 | Ekosonic |
| Shionogi INC | $20.72 | 2022 | |
| Tanabe Pharma America, INC. | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pardeep Masuta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.